Sartorius | SRT3 - Cost Of Sales

Stock Price
221.90
Daily Change
13.80 6.63%
Monthly
3.40%
Yearly
24.14%
Q2 Forecast
206.18

Sartorius reported EUR450M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Avita Medical AUD 3.3M 166K Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
IQVIA Holdings USD 3.24B 518M Dec/2025
Moderna USD 452M 245M Dec/2025
Organon & Co USD 745M 25M Sep/2025
Revvity USD 350.4M 26.05M Dec/2025
Sartorius EUR 450M 18.1M Sep/2025
Viatris USD 2.56B 167.3M Dec/2025
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025